2024.04.30
I-MAB Filed 2023 Annual Report on Form 20-F
ROCKVILLE, MD, April 30, 2024 – I-Mab (the “Company”) (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2023 with the U.S. […]